Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism.

ABSTRACT:

Introduction

To investigate the efficacy and safety of pulsatile gonadotropin-releasing hormone pump therapy in male infants with congenital hypogonadotropic hypogonadism.

Methods

Seven male infants with congenital hypogonadotropic hypogonadism who were treated in a single center between 2019 and 2022 were included. Each patient was treated by subcutaneous infusion of 5 μg/90 min gonadorelin via a pulsatile gonadotropin-releasing hormone pump for 3-5 months. Data including age, drug dose, penile length, testicular volume and cryptorchidism were collected. Serum testosterone, follicle-stimulating hormone, luteinizing hormone, anti-Müllerian hormone, inhibin B concentration and liver and kidney functions were also measured. Data were analyzed using paired t-test and rank-sum t

SUBMITTER: Wang X 

PROVIDER: S-EPMC11964480 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature